Active substanceFluconazoleFluconazole
Similar drugsTo uncover
  • Vero-Fluconazole
    capsules inwards 
    VEROPHARM SA     Russia
  • Disorel-Sanovel
    capsules inwards 
  • Diflazon®
    solution d / infusion 
  • Diflucan®
    powder inwards 
    Pfizer Inc.     USA
  • Diflucan®
    capsules inwards 
    Pfizer Inc.     USA
  • Diflucan®
    solution in / in 
    Pfizer Inc.     USA
  • Micon
    solution d / infusion 
  • Medoflucon®
    capsules inwards 
    MEDSERV, LLC     Russia
  • Mycomomax®
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Mycosyst®
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Mycosyst®
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Mycoflucan®
    pills inwards 
  • Mycoflucan®
    solution d / infusion 
  • Nofung®
    capsules inwards 
  • Procanazole
    capsules inwards 
  • Fangifflu
    capsules inwards 
  • Flukozan
    solution d / infusion 
    LENS-PHARM, LLC     Russia
  • Flukoside
    capsules inwards 
  • Flukomabol®
    solution d / infusion 
    PREBAND PFC, LLC     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    PHARMACY 36.6, CJSC     Russia
  • Fluconazole
    solution d / infusion 
  • Fluconazole
    capsules inwards 
  • Fluconazole
    solution d / infusion 
    RUSYUROFARM, LLC     Russia
  • Fluconazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Fluconazole
    capsules inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Fluconazole
    capsules inwards 
    FARMPROJECT, CJSC     Russia
  • Fluconazole
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    OZONE, LLC     Russia
  • Fluconazole
    capsules inwards 
    BIOKOM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    VERTEKS, AO     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    pills inwards 
    TECHNOLOG, JSC     Ukraine
  • Fluconazole
    capsules inwards 
    Hemofarm AD     Serbia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    Astrafarm, CJSC     Russia
  • Fluconazole
    capsules inwards 
    MEDISORB, CJSC     Russia
  • Fluconazole OBL
    capsules inwards 
  • Fluconazole Zentiva
    solution d / infusion 
    Zentiva c.s.     Czech Republic
  • Fluconazole Cabi
    solution d / infusion 
  • Fluconazole STADA
    capsules inwards 
  • Fluconazole-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Fluconazole-Sandoz®
    capsules inwards 
    Sandoz d.     Slovenia
  • Fluconazole-Teva
    capsules inwards 
  • Flukonorm
    capsules inwards 
  • Flucorus®
    solution d / infusion 
    MS-VITA, LLC     Russia
  • Flukorem
    gel externally 
    REMEDIYA, LLC     Russia
  • Flucostat®
    solution d / infusion 
  • Flucostat®
    capsules inwards 
  • Forkan®
    solution d / infusion 
    Cipla Ltd.     India
  • Forkan®
    capsules inwards 
    Cipla Ltd.     India
  • Ciscan®
    capsules inwards 
  • Dosage form: & nbspcapsules
    Composition:

    active substance: fluconazole - 50 mg or 150 mg;

    Excipients:

    lactose monohydrate - 137.4 mg or 138.7 mg, pregelatinized starch - 46.6 mg or 52.5 mg, silicon dioxide colloiden (aerosil) - 2.4 mg or 3.5 mg, magnesium stearate - 2.4 mg or 3.5 mg, sodium lauryl-sulfate - 1.2 mg or 1.8 mg;

    hard gelatine capsules:

    for a dosage of 50 mg -

    body: titanium dioxide E 171 - 2%, desired

    tin-up to 100%;

    cap: titanium dioxide E 171 - 2%, the edgesazorubin E 122 - 0.0205%, dye Crimson [Ponso 4R] E 124 - 0.0120%, the samelatin-up to 100%;

    for a dosage of 150 mg -

    body: titanium dioxide E 171 - 2%, gelatin-up to 100%;

    cap: titanium dioxide E 171 -2%, dye crimson [Ponso 4R] Е 124 - 0,1111%, dye sunset yellow E 110-0.3285%, gelatin - up to 100%.

    Description:
    for a dosage of 50 mg: capsule number 2, body white, cap pink; for a dosage of 150 mg: capsule number 1, body white, cap pinkish-orange. The contents of capsules are white or white powder with a yellowish tinge.

    Pharmacotherapeutic group:Antifungal agent.
    ATX: & nbsp

    J.02.A.C   Triazole derivatives

    J.02.A.C.01   Fluconazole

    Pharmacodynamics:
    Antifungal agent, has a highly specific effect, inhibiting the activity of enzymes of fungi, dependent on cytochrome P450. It blocks the transformation of the lanosterol of fungal cells into membrane lipid-ergosterol; increases the permeability of the cell membrane, disrupts its growth and replication.
    Fluconazole, being highly selective for cytochrome P450 fungi, practically does not inhibit these enzymes in the human body (in comparison with itraconazole, clotrimazole,econazole and ketoconazole to a lesser extent suppresses oxidative processes dependent on cytochrome P450 in human liver microsomes). Does not have anti-androgenic activity.
    Active with opportunistic fungal infections, incl. caused by Candida spp. (including generalized forms of candidiasis on the background of immunodepression), Cryptococcus neoformans and Coccidioides immitis (including intracranial infections), Microsporum spp. and Trichophyton spp; with endemic mycoses caused by Blastomyces dermatidis, Histoplasma capsulatum (including with immunodepression).

    Pharmacokinetics:
    After oral administration fluconazole well absorbed, food intake does not affect the rate of absorption of fluconazole, its bioavailability is 90%.
    Time to reach the maximum concentration in the blood plasma after ingestion, fasting 150 mg of the drug - 0.5-1.5 hours and 90% of the concentration in the plasma with intravenous administration at a dose of 2.5 - 3.5 mg / l. The half-life of fluconazole is 30 hours. The connection with plasma proteins is 11-12%. The concentration in the plasma is in direct proportion to the dose. 90% level of equilibrium concentration is reached by 4-5 days of treatment with the drug (with the administration of 1 time / day).
    The introduction of a "shock dose" (on the first day), which is 2 times higher than the usual daily dose,corresponding to 90% of the equilibrium concentration, by the second day.
    Fluconazole well penetrates into all body fluids. The concentration of the active substance in breast milk, articular fluid, saliva, sputum and peritoneal fluid is similar to its levels in plasma. Constant values ​​in the vaginal secretion are reached 8 hours after ingestion and are held at this level for at least 24 hours. Fluconazole well penetrates into the cerebrospinal fluid (CSF), with fungal meningitis, the concentration in the CSF is about 85% of its plasma level. In the fluid, epidermis and stratum corneum (selective accumulation), concentrations exceeding serum levels are achieved. After oral administration of a dose of 150 mg on day 7, the fluconazole concentration in the stratum corneum is 23.4 μg / g, and 1 week after the second dose, 7.1 μg / g; concentration in the nails after 4 months of application at a dose of 150 mg once a week - 4.05 μg / g in healthy and 1.8 μg / g in the affected nails. The volume of distribution approximates the total water content in the body.
    It is an inhibitor of the isoenzyme CYP2C9 in the liver. It is excreted mainly by the kidneys (80% - unchanged, 11% - in the form of metabolites). The clearance of fluconazole is proportional to the creatinine clearance.Metabolites of fluconazole in peripheral blood were not detected.
    The pharmacokinetics of fluconazole significantly depend on the functional state of the kidneys, and there is an inverse relationship between the half-life and the clearance of creatinine. After hemodialysis for 3 hours the concentration of fluconazole in plasma is reduced by 50%.

    Indications:
    • cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), both in patients with normal immune response, and in patients with various forms of immunosuppression (including those with AIDS, organ transplantation ); the drug can be used to prevent cryptococcal infection in AIDS patients;
    • generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis infections (peritoneal, endocardial, eye, respiratory and urinary tract infections). Treatment can be performed in patients with malignant neoplasms, in intensive care units, in patients undergoing cytostatic or immunosuppressive therapy, and in the presence of other factors predisposing to the development of candidiasis;
    • Candidiasis of mucous membranes, incl.oral cavity and pharynx (including atrophic candidiasis of the oral cavity, associated with the wearing of dentures), esophagus, non-invasive bronchopulmonary candidiasis, candiduria, candidiasis of the skin; prevention of recurrence of oropharyngeal candidiasis in AIDS patients;
    • genital-candidiasis: vaginal candidiasis (acute and chronic recurrent), preventive use to reduce the frequency of recurrences of vaginal candidiasis (3 or more episodes per year); Candidiasis balanitis;
    • prevention of fungal infections in patients with malignant neoplasms that are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy;
    • mycosis of the skin, including mycosis of the feet, the body, the groin area; pityriasis (multicolored) lichen, onychomycosis; candidiasis of the skin;
    • Deep endemic mycoses, including coccidiomycosis, paracoccidiomycosis, sporotrichosis and histoplasmosis in patients with normal immunity.

    Contraindications:
    • hypersensitivity to the drug (including other azole antifungal drugs in history),
    • simultaneous reception of terfenadine (against the background of a constant intake of fluconazole at a dose of 400 mg / day or more) or astemizole,as well as other drugs that extend the QT interval;
    • children's age up to 4 years.

    Carefully:
    : Hepatic and / or renal failure, occurrence of rash on the background of fluconazole in patients with superficial fungal infection and invasive GOVERNMENTAL / systemic fungal infections, simultaneous terfenadine and fluconazole less than 400 mg / day, simultaneous reception of potentially hepatotoxic drugs, alcohol , potentially proaritmogenic states in patients with multiple risk factors (organic heart disease, electrolyte balance disorders, simultaneous reception of medication TV, causing arrhythmias), pregnancy.

    Pregnancy and lactation:
    Use of the drug in pregnant women - is inappropriate, except severe or life-threatening forms of fungal infections, where the potential benefits from the use of fluconazole for the mother is much higher than the risk to the fetus.
    Since fluconazole concentration in breast milk and plasma is the same, to apply the drug during lactation - is contraindicated.

    Dosing and Administration:
    Inside.
    Adults and children over 15 years of age (body weight over 50 kg) with cryptococcal meningitis and cryptococcal infections of other locations on the first day are usually prescribed 400 mg (8 capsules of 50 mg), and then continue treatment at a dose of 200 mg (4 capsules of 50 mg ) - 400 mg (8 capsules of 50 mg) once a day. The duration of treatment for cryptococcal infections depends on the clinical efficacy, confirmed by mycological examination; when cryptococcal meningitis treatment course should be at least 6-8 weeks.
    To prevent the recurrence of cryptococcal meningitis in AIDS patients, after completion of the full course of primary therapy, fluconazole prescribe a dose of 200 mg (4 capsules of 50 mg) per day for a long period of time.
    When candidemia, disseminated candidiasis and other invasive candidiasis infections on the first day of the dose is 400 mg (8 capsules of 50 mg), and then - 200 mg (4 capsules of 50 mg) per day. With insufficient clinical effectiveness, the dose of the drug can be increased to 400 mg (8 capsules 50 mg) per day. The duration of therapy depends on clinical effectiveness.
    With oropharyngeal candidiasis, the drug is usually prescribed for 150 mg 1 time / day; the duration of treatment is 7-14 days.If necessary, in patients with a marked decrease in immunity, treatment may be longer. -
    To prevent the recurrence of oropharyngeal candidiasis in AIDS patients after completing the full course of primary therapy - 150 mg once a week.
    With atrophic oral candidiasis associated with the wearing of dentures, 50 mg once a day for 14 days in combination with local antiseptic medicines to treat the prosthesis.
    For other candidiasis localizations (with the exception of genital candidiasis), for example, with esophagitis, non-invasive bronchopulmonary disease, candiduria, candidiasis of the skin and mucous membranes, etc., the effective dose is usually 150 mg / day with a treatment duration of 14-30 days.
    With vaginal candidiasis fluconazole taken once inside the dose of 150 mg. To reduce the frequency of recurrences of vaginal candidiasis, the drug can be used at a dose of 150 mg once a month. The duration of therapy is determined individually;
    it varies from 4 to 12 months. Some patients may need more frequent use.
    With balapitis caused by Candida, fluconazole is administered orally once a day at a dose of 150 mg per day.
    For the prevention of candidiasis, the recommended dose is 50-400 mg once a day, depending on the degree of risk of fungal infection. For the prevention of candidiasis in patients with malignant neoplasms the recommended dose of fluconazole is 150-400 mg 1 time / day, depending on the degree of risk of fungal infection. If there is a high risk of generalized infection, for example, in patients with expected severe or persistent neutropenia, the recommended dose is 400 mg / day. Fluconazole appoint a few days before the expected appearance of neutropenia; after the increase in the number of neutrophils more than 1 thousand / μl treatment is continued for another 7 days.
    With mycosis of the skin, including mycosis of the feet, skin of the inguinal region, and skin candidiasis, the recommended dose is 150 mg once a week or 50 mg once a day, the dosage regimen depends on the clinical and mycological effect. Duration of therapy in usual cases is 2-4 weeks, however, with foot mycoses, longer therapy (up to 6 weeks) may be required.
    With pityriasis - 300 mg (2 capsules of 150 mg) once a week for 2 weeks, some patients require a third dose of 300 mg per week,while in some cases it is sufficient to receive 300-400 mg once; an alternative treatment regimen is to apply 50 mg once a day for 2-4 weeks.
    With onychomycosis, the recommended dose is 150 mg once a week. Treatment should continue until the replacement of the infected nail (the growth of the uninfected nail). For the repeated growth of the nails on the fingers and toes normally takes 3-6 months. and 6-12 months. respectively.
    With deep endemic mycoses, it may be necessary to use the drug at a dose of 200 mg (4 capsules of 50 mg) - 400 mg (8 capsules 50 mg) per day for up to 2 years. The duration of therapy is determined individually; it can be 11-24 months with coccidioidomycosis: 2-17 months. with paracoccidioidomycosis: 1-16 months. with sporotrichosis and 3-17 months. with histoplasmosis.
    In children, as with similar infections in adults, the duration of treatment depends on the clinical and mycological effect. In children, the drug should not be used in a daily dose that would exceed that in adults, i.e. not more than 400 mg per day. The drug is used daily 1 time / day.
    Application of Fluconazole 50 mg capsules in children from 4 to 15 years of age

    Diseases

    Weight and weight of the child


    4-6 years the average weight of the child is 15-20 kg

    7-9 years old child's average weight 21-29 kg

    10-12 years the average weight of the child is 30-40 kg

    12-15 years old the average child weight is 40-50 kg

    Candidiasis of the esophagus (3 mg / kg/ cvm)

    1 capsule 50 mg per day

    1-2 capsules 50 mg per day

    2 capsules of 50 mg once

    2-3 capsules of 50 mg once

    Treatment period

    For at least 3 weeks and within 2 weeks after regression of symptoms.

    Candidiasis of mucous membranes

    (3 mg / kg/ cvm)

    On the 1st day: 2-3 capsules

    Next: 1 capsule per day

    In the 1st day: 2-4 capsules Next: 1-2 capsules per day

    On the 1st day: 4-5 capsules

    Further: 2 capsules per day once

    On the 1st day: 5-6 capsules

    Next: 2-3 capsules per day once

    Treatment period

    On the first day, a shock dose is given in order to achieve a more rapid steady-state equilibrium concentration, then the treatment is continued for at least 3 weeks.

    Generalized candidiasis and cryptococcal infection (including meningitis)

    6-12 mg / kg / day

    2-5 capsules per day

    2-6 capsules per day

    4-7 capsules per day

    5-8 capsules per day

    Treatment period

    Within 10-12 weeks (before laboratory confirmation of absence of pathogens in CSF)

    Prevention of fungal infections in

    children with reduced immunity,at which the risk of infection is associated with neutropenia, resulting from cytotoxic chemotherapy or radiotherapy PZ-12 mg / kg / day

    1-5 capsules per day

    1-6 capsules per day

    2-7 capsules per day

    2-8 capsules per day

    Treatment period

    The drug is given in doses, depending on the severity and duration of preservation of induced neutropenia.


    In children with impaired renal function, the daily dose of the drug should be reduced (in the same proportional relationship as in adults), according to the degree of renal insufficiency.
    In elderly patients in the absence of violations of kidney function should follow the usual dosage regimen. Patients with renal insufficiency (creatinine clearance less than 50 ml / min) dosage regimen should be adjusted as indicated below.
    Fluconazole is excreted mainly with urine in unchanged form. In chronic renal failure, a "shock" dose of 50-400 mg is initially administered. If the clearance of creatinine (CC) is more than 50 ml / min, the usual dose of the drug (100% of the recommended dose) is used. With SC from 11 to 50 ml / min 50% of the recommended dose or usual dose is applied once every 2 days.
    In patients with impaired renal function, the drug is used according to the following scheme:

    Creatinine clearance

    Interval / daily dose

    1. > 40 ml / min

    2. 21-40 ml / min

    3. 10-20 ml / min

    1. 24 hours (normal dosing regimen)

    2. 48 hours (1 time in 2 days) or half the usual daily dose (1 time in 24 hours)

    3. 72 hours (1 every 3 days) or a third of the usual daily dose (1/3 in 24 hours)

    Patients regularly on dialysis, one dose of the drug is used after each session of hemodialysis.



    Side effects:
    On the part of the digestive system: decreased appetite, changes in taste, abdominal pain, vomiting, nausea, diarrhea, flatulence, abdominal pain, rarely - liver dysfunction (jaundice, hepatitis, hepatonecrosis, hyperbilirubinemia, increased activity of alanine aminotransferases, aspartate aminotransferase, increased alkaline phosphatase activity , hepatocellular necrosis), incl. heavy.
    From the nervous system: headache, dizziness, excessive fatigue, rarely - convulsions.
    From the hemopoiesis: rarely - leucopenia, thrombocytopenia (bleeding, petechiae), neutropenia, agranulocytosis.
    Allergic reactions: skin rash, rarely - multiforme exudative erythema (incl.Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions (including angioedema, facial edema, urticaria, skin itching).
    From the cardiovascular system: an increase in the duration of the Q-T interval, fibrillation / flutter of the ventricles.
    Other: rarely - renal dysfunction, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

    Overdose:
    Symptoms: hallucinations, paranoid behavior.
    Treatment: symptomatic: gastric lavage, forced diuresis. Hemodialysis within 3 hours reduces the plasma concentration by approximately 50%.

    Interaction:
    When using fluconazole with warfarin, prothrombin time increases (on average by 12%). In this regard, it is recommended that the parameters of prothrombin time be carefully monitored in patients receiving the drug in combination with coumarin anticoagulants.
    Fluconazole increases the half-life of plasma from oral hypoglycemic agents - sulfonylurea derivatives (chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy people.Joint use of fluconazole and oral hypoglycemic agents in diabetic patients is allowed, but the doctor should keep in mind the possibility of developing hypoglycemia.
    The simultaneous use of fluconazole and phenytoin may lead to an increase in the concentration of phenytoin in plasma to a clinically significant degree. Therefore, when it is necessary to jointly use these drugs, it is necessary to monitor the concentrations of phenytoin with correction of its dose in order to maintain the drug level within the therapeutic interval.
    The combination with rifampicin leads to a 25% decrease in bioavailability (AUC) and a 20% decrease in the half-life of fluconazole from the plasma. Therefore, patients receiving concomitantly rifampicin, it is advisable to increase the dose of Fluconazole. It is recommended to monitor the concentration of cyclosporine in the blood in patients receiving Fluconazole, since the use of fluconazole and cyclosporine in patients with kidney transplantation taking Fluconazole at a dose of 200 mg / day leads to a slow increase in the concentration of cyclosporine in the plasma.
    Patients who receive high doses of theophylline or who are likely to develop theophylline intoxication,should be monitored for the early detection of symptoms of an overdose of theophylline, as taking fluconazole leads to a decrease in the average clearance rate of theophylline from the plasma.
    With the simultaneous use of fluconazole and terfenadine, cisapride, cases of unwanted reactions from the heart, including paroxysms of ventricular tachycardia (torsades de points), are described.
    Simultaneous use of fluconazole and hydrochlorothiazide can lead to an increase in the concentration of fluconazole in plasma by 40%.
    There have been reports of an interaction between fluconazole and rifabutin, accompanied by an increase in serum levels of the latter. With the simultaneous use of fluconazole and rifabutin, cases of uveitis are described. It is necessary to carefully observe patients who simultaneously receive rifabutin and fluconazole.
    In patients receiving a combination of fluconazole and zidovudine, an increase in the concentration of zidovudine is observed, which is caused by a decrease in the conversion of the latter into its main metabolite, so an increase in the side effects of zidovudine should be expected.
    Increases the concentration of midazolam, which increases the risk of developing psychomotor effects (most pronounced when fluconazole is administered orally).
    Increases the concentration of tacrolimus, in connection with which, the risk of nephrotoxic action increases.
    The combined use of fluconazal and combined oral contraceptives containing ethinyl estradiol and levonorgestrel, does not have a significant effect on the level of hormones, but in some patients there was a decrease in ethinylestradiol by 40% and levonorgestrel by 33%.
    The simultaneous use of fluconazole in patients receiving astemizole or other drugs metabolized by the cytochrome P450 system, may be accompanied by an increase in the concentration of these drugs in serum. For such patients need to be carefully monitored.

    Special instructions:
    Treatment should continue until the appearance of clinical-hematologic remission. Premature termination of treatment leads to relapse.
    In rare cases, the use of fluconazole was accompanied by toxic changes in the liver, incl. with a fatal outcome, mainly in patients with serious concomitant diseases. In the case of hepatotoxic effects associated with fluconazole, there was no apparent dependence on total daily dose, duration of therapy, sex, and age of the patient.The hepatotoxic effect of fluconazole was usually reversible; signs of it disappeared after discontinuation of therapy. If there are clinical signs of liver damage that may be associated with fluconazole, the drug should be discontinued.
    Patients with AIDS are more likely to develop severe skin reactions with many drugs. In those cases where the rash develops in patients with superficial fungal infection and it is regarded as definitely associated with fluconazole, the drug should be discontinued. When rashes appear in patients with invasive / systemic fungal infections, they should be carefully monitored and canceled fluconazole when there are bullous changes or erythema multiforme.
    Caution should be exercised with simultaneous administration of fluconazole with cisabode, rifabutin, or other drugs metabolized by the cytochrome P 450 system.

    Form release / dosage:
    Capsules 50 mg and 150 mg.

    Packaging:
    For 7 capsules of a dosage of 50 mg or 1 capsule of a dosage of 150 mg are placed in a contour mesh box made of a polyvinylchloride film and aluminum foil printed lacquered.
    I contour mesh packaging together with the instruction for use is placed in a pack of cardboard.
    Storage conditions:
    In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N002782 / 01
    Date of registration:29.01.2009
    The owner of the registration certificate:VALENTA PHARM, PAO VALENTA PHARM, PAO Russia
    Manufacturer: & nbsp
    Representation: & nbspVALENTA PHARM, PAO VALENTA PHARM, PAO Russia
    Information update date: & nbsp15.10.2015
    Illustrated instructions
      Instructions
      Up